drugset / Trial / NCT07050173

Monitoring Patients With Repetitive Head Impact With Gamma-glutamylcysteine Supplementation

NCT07050173 ↗

Phase 1 Recruiting 30 enrolled Pravat Mandal Chuck Noll Foundation · collab
NaSingle-groupOpen-labelPrevention

Summary

The goal of this clinical trial is to test whether the gamma - glutamylcystiene (GGC) oral supplement can reach the brain and subsequently increase antioxidant glutathione (GSH) level in people with repetitive head impact (RHI). This will reduce the oxidative stress related injury in people with RHI.This unique study's main objective is to test the: 1. Change in GSH in brain and blood levels through GGC supplementation. 2. Change in the cognitive function in RHI patients due to GGC supplementation.

Timeline

Start
2026-05-01
Primary completion
2027-11-01
Completion
2027-12-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Gamma Glutamylcysteine Unknown 400 mg Oral

Indications

No indication recorded.